<DOC>
	<DOCNO>NCT00108485</DOCNO>
	<brief_summary>The primary purpose study test effectiveness tolerability Niaspan® improve level blood fat ( `` good '' `` bad '' cholesterol triglyceride level ) people kidney damage due diabetes . A secondary goal test whether Niaspan® slow development kidney damage .</brief_summary>
	<brief_title>Study Use Niaspan Treatment Dyslipidemia Diabetic Nephropathy</brief_title>
	<detailed_description>Diabetic nephropathy lead cause end stage kidney disease United States . Patients chronic kidney disease markedly increase risk death cardiovascular disease , traditional risk factor hyperlipidemia show critical importance . Almost 90 % patient diabetes chronic kidney disease lipid abnormality . Here , investigate whether Niaspan , take addition lipid-lowering drug refer `` statin '' , decrease LDL cholesterol increase LDL particle size , increase HDL , reduce proteinuria , reduce speed loss renal function .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Diagnosis type 2 diabetes Diagnosis chronic kidney disease stage 2 3 estimate GFR 3089 ml/min use four variable MDRD ( Modification Diet Renal Disease Study Group ) formula Presence microalbuminuria proteinuria less 3.5 g/d Diagnosis hyperlipidemia currently treat `` statin '' drug Not meet inclusion criterion HDLC &gt; 40 mg/dL men , &gt; 50 mg/dL woman TG ( triglyceride ) &lt; 150 mg/dL &gt; 800 mg/dL Documented intolerance Niaspan Aspirin Treatment lipidlowering agent ( fibrates , BAS [ bile acid sequestrants ] , ezetimibe ) Elevated transaminase ( AST ALT &gt; 1.3 x ULN ) Unstable type 2 diabetes ( FBG &gt; 200 mg/dL HbA1c &gt; 9.5 % ) Known seropositivity Hepatitis B , C , HIV Documented history malignancy Age &lt; 18 year Pregnant woman nurse mother Inability give inform consent Start change `` statin '' dose &lt; 2 month ago</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Randomized Controlled Trials</keyword>
</DOC>